Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer

We investigated the association between TP53 mutation and 21-gene recurrence score {RS) in ER-positive/HER2-negative breast cancer (BC) using data from 141 patients who underwent TP53 sequencing and Oncotype DX (R) tests. We detected TP53 mutations in 18 (12.8%) patients. Most patients with TP53 mutation had a high 21-gene RS {>= 26). The average 21-gene RS was higher in TP53 mutant tumors. Multivariate analysis showed that mutated TP53 is an independent factor for a high 21-gene RS. Mutated TP53 remained closely associated with high 21-gene RS in patients with low pathological risk (n = 103). In the ER+/PR+/HER2-negative subset (n = 356) of The Cancer Genome Atlas, the non-luminal A intrinsic subtype was more prevalent in the group with mutant TP53. mRNA levels of p53-regulated senescence gatekeeper and cell cycle-related genes were increased in BC with mutated TP53. Mutational analysis of TP53 helped identify endocrine-resistant tumors.

Automated summary

The association between TP53 gene mutation and 21-gene recurrence score (RS) in ER-positive/HER2-negative breast cancer was investigated. The study found that TP53 mutation was correlated with high 21-gene RS. This correlation remained significant in patients with low pathological risk. In addition, TP53 mutation was associated with the non-luminal A intrinsic subtype in the subset of ER+/PR+/HER2-negative breast cancer.